Clinical trials: Active Acne
Acne Vulgaris
Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris
This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1% gel (Akorn), and the marketed product Clindamycin 1% gel…
- Trial name
- NCT03522441
- Testing
- Clindamycin 1% Gel
- Where
- 12 sites in United States, Belize
- Volunteers
- 1,125 people
- Sponsor
- Akorn, Inc.
Acne Vulgaris
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
Bioequivalence with Clinical Endpoints.
- Trial name
- NCT02709902
- Testing
- Adapalene/BP gel, 0.3%/2.5%, EPIDUO® FORTE
- Volunteers
- 460 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne…
- Trial name
- NCT02886715
- Testing
- Tazarotene Cream 0.1%, Tazorac®
- Where
- 25 sites in United States
- Volunteers
- 1,110 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Acne Vulgaris
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
This is a multicenter, randomized, single-blinded (investigator's blinded), active-controlled (clindamycin [CLDM] 1% gel), parallel-group study in Japanese subjects with acne vulgaris to demonstrate the efficacy of GSK2585823…
- Trial name
- NCT01445301
- Testing
- GSK2585823(CLDM 1%-BPO 3% gel), CLDM 1% gel twice daily
- Where
- 26 sites in Japan
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
Acne Vulgaris
Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris
To compare the safety and efficacy profiles of Tazarotene Cream, 0.1 % to the reference listed drug Tazorac® (tazarotene) Cream, 0.1 % in order to demonstrate bioequivalence, and to demonstrate superiority of the 2 active creams…
- Trial name
- NCT02160678
- Testing
- Vehicle, Tazarotene Cream, 0.1 %, Tazorac Cream, 0.1%
- Where
- United States
- Volunteers
- 1,741 people, healthy volunteers welcome
- Sponsor
- G & W Laboratories Inc.
Acne Vulgaris, Toxoplasmosis
Evaluation of the Role of Latent Toxoplasmosis in Female Patients With Active Acne Vulgaris
Acne vulgaris is one if the most common chronic inflammatory skin disorders.Acne is characterized by forming of inflammatory and non inflammatory lesions mainly on the Face,neck,arms, upper trunk and back
- Trial name
- NCT05783778
- Testing
- Free testosterone levels and toxoplasma igG
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sohag University